Labcorp’s first quarter was marked by continued growth in both its Diagnostics and Biopharma Laboratory Services businesses, supported by strategic partnerships and acquisitions. Management credited the quarter’s results to volume gains in specialty testing areas such as neurology and oncology, as well as successful integration of acquired laboratory assets. CEO Adam Schechter highlighted the company’s nationwide collaboration with the Children’s Hospital of Philadelphia and new test launches, particularly in Alzheimer’s and liquid biopsy diagnostics, as notable contributors. The impact of adverse weather was called out as a modest headwind to organic volume growth, though it did not materially alter the quarter’s overall performance.
Is now the time to buy LH? Find out in our full research report (it’s free for active Edge members).
Labcorp (LH) Q1 CY2026 Highlights:
- Revenue: $3.54 billion vs analyst estimates of $3.51 billion (5.8% year-on-year growth, 0.9% beat)
- Adjusted EPS: $4.25 vs analyst estimates of $4.12 (3.3% beat)
- Adjusted EBITDA: $601.9 million vs analyst estimates of $604.5 million (17% margin, in line)
- The company slightly lifted its revenue guidance for the full year to $14.73 billion at the midpoint from $14.7 billion
- Management slightly raised its full-year Adjusted EPS guidance to $18.03 at the midpoint
- Operating Margin: 10.8%, up from 9.7% in the same quarter last year
- Organic Revenue rose 3.1% year on year (miss)
- Market Capitalization: $21.07 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Labcorp’s Q1 Earnings Call
- Lisa Gill (JPMorgan) asked about the impact of adverse weather and ACA exchange volume changes; CEO Adam Schechter estimated a $15 million weather impact and noted ACA-related volume effects were minimal in Q1 but could total 30 basis points for the year.
- Jack Meehan (Nephron Research) questioned exposure to the CMS CRUSH initiative; Schechter responded that Labcorp supports fraud reduction efforts but stressed the need to avoid unintended consequences for legitimate providers.
- Michael Cherny (Leerink Partners) probed on test mix and volume trajectory in Diagnostics; Schechter explained that specialty tests are driving higher test-per-accession rates and higher margins, supporting margin expansion.
- Patrick Donnelly (Citi) inquired about Biopharma Laboratory Services bookings and book-to-bill trends; Schechter noted Central Labs are the growth engine, with a healthy pipeline and expected sequential improvement in bookings.
- David Westenberg (Piper Sandler) asked about investments and growth in consumer testing; Schechter stated that Labcorp OnDemand is growing double digits, with ongoing investment in new products and targeted marketing, focusing on high-margin segments.
Catalysts in Upcoming Quarters
Looking ahead, our team will monitor (1) the adoption and engagement metrics for the MyLabcorp app and other digital health initiatives, (2) the trajectory of specialty testing growth, especially in Alzheimer’s and oncology, and (3) the pace and financial impact of newly announced hospital partnerships and acquisitions. Progress in automation and regulatory developments, such as PAMA reporting outcomes, will also be important to track.
Labcorp currently trades at $258.47, in line with $257.14 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
